Boehringer Ingelheim
@boehringerglobal.bsky.social
Join the conversation on the latest in healthcare innovation for humans and animals. #LifeForward
Imprint: https://www.boehringer-ingelheim.com/imprint
Privacy notice: https://www.boehringer-ingelheim.com/privacy-notice
Imprint: https://www.boehringer-ingelheim.com/imprint
Privacy notice: https://www.boehringer-ingelheim.com/privacy-notice
#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
January 28, 2026 at 6:38 AM
#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease
This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm
This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm
January 27, 2026 at 9:20 AM
#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease
This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm
This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm
#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
December 19, 2025 at 5:30 PM
#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
Understanding and treating HER2driven lung cancer is a critical need.
In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research.
Learn more here: LCRF.org/251209bi
In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research.
Learn more here: LCRF.org/251209bi
December 11, 2025 at 4:46 PM
Understanding and treating HER2driven lung cancer is a critical need.
In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research.
Learn more here: LCRF.org/251209bi
In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research.
Learn more here: LCRF.org/251209bi
Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T
#medsky #pharmsky
#medsky #pharmsky
December 11, 2025 at 10:01 AM
Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T
#medsky #pharmsky
#medsky #pharmsky
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
December 10, 2025 at 10:58 AM
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA.
Find out more here go.boehringer.com/Fyr8N
#LifeForward #Oncology
Find out more here go.boehringer.com/Fyr8N
#LifeForward #Oncology
November 10, 2025 at 1:55 PM
#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA.
Find out more here go.boehringer.com/Fyr8N
#LifeForward #Oncology
Find out more here go.boehringer.com/Fyr8N
#LifeForward #Oncology
#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl
November 4, 2025 at 1:42 PM
#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl
#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪
Learn more: go.boehringer.com/MPRF
#Innovation #AutoimmuneDiseases #PharmSky
Learn more: go.boehringer.com/MPRF
#Innovation #AutoimmuneDiseases #PharmSky
October 30, 2025 at 10:59 AM
#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪
Learn more: go.boehringer.com/MPRF
#Innovation #AutoimmuneDiseases #PharmSky
Learn more: go.boehringer.com/MPRF
#Innovation #AutoimmuneDiseases #PharmSky
#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF).
🧪 Learn more here: go.boehringer.com/HdX1
🧪 Learn more here: go.boehringer.com/HdX1
October 22, 2025 at 9:18 AM
#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF).
🧪 Learn more here: go.boehringer.com/HdX1
🧪 Learn more here: go.boehringer.com/HdX1
The immune system has the remarkable ability to identify and eliminate cancer cells.
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
October 20, 2025 at 7:57 AM
The immune system has the remarkable ability to identify and eliminate cancer cells.
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
October 17, 2025 at 2:05 PM
#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
Living with cancer, the small, positive moments often have the biggest impact.
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
October 16, 2025 at 9:48 AM
Living with cancer, the small, positive moments often have the biggest impact.
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
October 10, 2025 at 2:48 PM
#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
#NEWS: The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪
Learn more here: go.boehringer.com/rtx-w
#LifeForward
Learn more here: go.boehringer.com/rtx-w
#LifeForward
October 9, 2025 at 10:02 AM
#NEWS: The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪
Learn more here: go.boehringer.com/rtx-w
#LifeForward
Learn more here: go.boehringer.com/rtx-w
#LifeForward
#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪
#ERS2025 #LifeForward
#ERS2025 #LifeForward
September 29, 2025 at 6:46 AM
#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪
#ERS2025 #LifeForward
#ERS2025 #LifeForward
#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪
Find out more here: go.boehringer.com/dz4O
Find out more here: go.boehringer.com/dz4O
September 9, 2025 at 10:52 AM
#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪
Find out more here: go.boehringer.com/dz4O
Find out more here: go.boehringer.com/dz4O
#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs. 🧪
Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL
Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL
September 8, 2025 at 2:38 PM
#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs. 🧪
Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL
Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL
We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪
Learn more: go.boehringer.com/HP-j5
#LungHealth #IPF
Learn more: go.boehringer.com/HP-j5
#LungHealth #IPF
September 2, 2025 at 1:42 PM
We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪
Learn more: go.boehringer.com/HP-j5
#LungHealth #IPF
Learn more: go.boehringer.com/HP-j5
#LungHealth #IPF
#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪
Learn more here: go.boehringer.com/YrIQ
#LifeForward #Oncology
Learn more here: go.boehringer.com/YrIQ
#LifeForward #Oncology
September 1, 2025 at 9:04 AM
#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪
Learn more here: go.boehringer.com/YrIQ
#LifeForward #Oncology
Learn more here: go.boehringer.com/YrIQ
#LifeForward #Oncology
#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪
Learn more: go.boehringer.com/py5Iu
#EyeHealth #DiabeticRetinopathy #Innovation
Learn more: go.boehringer.com/py5Iu
#EyeHealth #DiabeticRetinopathy #Innovation
August 18, 2025 at 12:10 PM
#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪
Learn more: go.boehringer.com/py5Iu
#EyeHealth #DiabeticRetinopathy #Innovation
Learn more: go.boehringer.com/py5Iu
#EyeHealth #DiabeticRetinopathy #Innovation
At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
August 15, 2025 at 2:24 PM
At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov.
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
August 8, 2025 at 8:10 PM
#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov.
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF
August 7, 2025 at 2:32 PM
#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF
#NEWS: First Half of 2025
👉 EUR 14.0 billion in group net sales
👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch
👉 #AnimalHealth business grew by 7.6%
👉 Fast-growing pipeline in cardio-renal-metabolic diseases
Learn more ➡️ go.boehringer.com/w7ce3
👉 EUR 14.0 billion in group net sales
👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch
👉 #AnimalHealth business grew by 7.6%
👉 Fast-growing pipeline in cardio-renal-metabolic diseases
Learn more ➡️ go.boehringer.com/w7ce3
July 24, 2025 at 7:21 AM
#NEWS: First Half of 2025
👉 EUR 14.0 billion in group net sales
👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch
👉 #AnimalHealth business grew by 7.6%
👉 Fast-growing pipeline in cardio-renal-metabolic diseases
Learn more ➡️ go.boehringer.com/w7ce3
👉 EUR 14.0 billion in group net sales
👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch
👉 #AnimalHealth business grew by 7.6%
👉 Fast-growing pipeline in cardio-renal-metabolic diseases
Learn more ➡️ go.boehringer.com/w7ce3